NCT01667484

Adderall XR and Processing Speed in Multiple Sclerosis (MS)

Does Adderall XR Improve Processing Speed in Cognitively Impaired MS Patients?

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: London Health Sciences Centre · Academic / Other
• Sex: All
• Age: 18 Years – 59 Years
• Healthy volunteers: Not accepted

Summary

Cognitive impairment, or problems with thinking and memory, is common in multiple sclerosis (MS) and can occur independently of physical disability. It is the most common reason, along with physical fatigue, for MS patients to stop working. The most frequent complaint is problems with multi-tasking or thinking quickly, which corresponds to impairment in the cognitive domain of processing speed. Currently there is treatment available to prevent relapses and physical disability but there are no medications that have been shown to treat cognitive impairment. Amphetamines have been beneficial for selective attention and processing speed in attention deficit hyperactivity disorder (ADHD) and traumatic brain injury. This is study will determine whether Adderall XR improves objective measures of processing speed and attention in MS patients impaired in this cognitive domain, by comparing two doses of Adderall XR (5 and 10mg) to placebo before and after the medication is administered. The results of this study will help provide data to design a larger study to determine if Adderall XR, and potentially other amphetamine drugs, will help treat cognitive impairment in MS patients.

Conditions

• Impaired Processing Speed
• Cognitive Impairment
• Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	Adderall XR 5mg
DRUG	Adderall XR 10 mg
DRUG	Placebo

Timeline

• Start date: 2012-09-01
• Primary completion: 2013-02-01
• Completion: 2015-02-01
• First posted: 2012-08-17
• Last updated: 2015-05-12

Locations

1 site across 1 country: Canada